Canine Osteosarcoma Clinical Trial | ELIAS Animal Health
Depression is a significant problem for some breast cancer survivors after the end of treatment.
This study assessed depression using the CES‑D for 84 breast cancer patients at the conclusion of radiation treatment, and at 3 and 6 months post‑treatment. Based on the pattern of CES‑D scores, patients were divided into five groups (Stay Depressed, Recover, Become Depressed, Never Depressed, Vacillate). Relationships between these depression patterns and medical, demographic, and psychological measures (anxiety, quality of life, number of children at home) were examined.
Understanding stability and changes in depressive symptoms can inform psychosocial interventions to improve quality of life for breast cancer survivors.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC